Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes.
OBJECTIVE
(123)I cardiac meta-iodobenzylguanidine (MIBG), an analogue of norepinephrine, has been used to estimate myocardial sympathetic nerve function. We investigate whether cardiac-MIBG SPECT is clinically applicable in the differentiation of Parkinson's disease (PD) from parkinsonian syndromes.


METHODS
Cardiac-MIBG scintigraphy was performed in 27 controls, in 40 patients with PD and in 52 patients with other parkinsonian syndromes comprising 23 with multiple system atrophy (MSA), 26 with drug-induced parkinsonism (DIP), and 3 with corticobasal degeneration (CBD). The heart to mediastinum (H/M) uptake ratio was calculated for each subjects. Patients who either had medical conditions that confused the MIBG SPECT results or who took medications that interfere with MIBG accumulation were excluded from the study.


RESULTS
Both early and delayed H/M ratios were in patients with PD significantly lower than in controls (early, 1.34+/-0.15 vs 1.79+/-0.19; delayed, 1.29+/-0.15 vs 2.06+/-0.29, p<0.001). In patients with PD, both early and delayed H/M ratios were significantly lower than those in patients with MSA (early, 1.68+/-0.23; delayed, 1.80+/-0.34, p<0.001), DIP (early, 1.83+/-0.24; delayed, 2.07+/-0.4, p<0.001), or CBD (early, 1.85+/-0.01; delayed, 1.99+/-0.19, p<0.001). Two patients with DIP, who were within the range of patients with PD, showed clinically similar courses of PD.


CONCLUSIONS
This study demonstrates that cardiac-MIBG is a clinically powerful tools to differentiate PD from other parkinsonian syndromes.
Shin
Dong Hoon
DH
Department of Neurology, Ajou University School of Medicine, Suwon, South Korea.
Lee
Phil Hyu
PH
Bang
Oh Young
OY
Joo
In Soo
IS
Huh
Kyoon
K
J Neurol Sci. 2004 May 15;220(1-2):105-11
15140615
Lancet. 1984 Nov 10;2(8411):1082-3
6150149
Neurology. 1993 Mar;43(3 Pt 1):552-6
8451000
Nucl Med Commun. 1992 Jul;13(7):513-21
1495678
J Nucl Med. 1981 Apr;22(4):358-64
7205383
Ann Neurol. 1987 Dec;22(6):692-9
3435079
J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):776-7
12438492
Can J Neurol Sci. 1991 Aug;18(3):275-8
1913360
J Neurol Neurosurg Psychiatry. 1960 Nov;23:283-90
13711997
J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):529-34
12397145
J Neurol Sci. 1998 Feb 18;155(1):60-7
9562324
Hypertension. 1999 Jun;33(6):1447-52
10373231
Eur J Nucl Med. 2000 May;27(5):566-73
10853813
Neurology. 1967 May;17(5):427-42
6067254
J Neurol Sci. 1979 Sep;43(1):59-82
521829
J Nucl Med. 1986 Jan;27(1):37-44
3941363
Am J Physiol. 1987 Jun;252(6 Pt 1):E734-9
3296780
J Neurol Sci. 2000 Apr 1;175(1):3-12
10785250
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):850-4
2900293
Mov Disord. 2003 Oct;18 Suppl 7:S28-33
14531043
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
1564476
Ann Neurol. 2003;54 Suppl 5:S15-9
12833363
Mol Pharmacol. 1984 Nov;26(3):539-46
6493209
Mov Disord. 2003 Aug;18(8):890-7
12889078
J Nucl Med. 1981 Jan;22(1):22-31
7452352
Intern Med. 2003 Jan;42(1):127-8
12583635
Ann Neurol. 1978 Feb;3(2):129-33
350130
J Nucl Med. 1987 Oct;28(10):1625-36
3655915
Eur J Nucl Med. 2000 Mar;27(3):340-5
10774888
J Nucl Med. 1987 Oct;28(10):1620-4
3655914
J Neurol Sci. 1999 Feb 1;163(1):94-8
10223419